Kit Roes has been appointed Professor of Biostatistics at Radboud University/Radboud university medical center, with effect from 1 August 2019. Prior to this appointment, Roes was a Professor of Biostatistics and Clinical Trial Methodology at UMC Utrecht for more than 10 years.
Roes is a biostatistician with extensive experience in statistical applications, research and education. He is a noted expert in the field of clinical studies, methodology and quality of clinical research. His research mainly concentrates on innovative designs and the analysis of clinical research for rare disorders, a focus that fits well with the more individual patient-oriented treatment.
Radboud university medical center
At Radboud university medical center, Prof. Roes and his team will further expand the contribution of biostatistics to research. The combination of innovative designs for (clinical) research and the increasing possibilities offered by prediction and modelling offer the opportunity to evaluate new treatments and techniques more efficiently and thus bring them to the patient more quickly.
Educating students about statistics and biostatistics is extremely important to a number of programmes. Roes will participate in that effort by focusing on the innovations that are taking place in that field, including design and the increasing availability of large data sets.
About Kit Roes
Kit Roes (Nijmegen, 1961) studied mathematics at Radboud University. After graduation, he went to work as an adviser at Philips. He gained more than 10 years’ experience in quality improvement at various companies and in various settings. He earned a PhD in a related context, focusing on new statistical methods for process control.
Biostatistics became his focus when he began working at Organon. He now has more than 15 years’ experience in clinical and non-clinical research into drug development and he has contributed to the development and registration of new drugs in various therapeutic areas. He has been a professor at UMC Utrecht for the past 10 years, where he initiated and led the EU project Asterix about methodologies for clinical studies of rare diseases.
Prof. Roes is chair of the Methodology work group at the College ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board) and a member of the Biostatistics Working Party at the European Medicines Agency. He is also an adviser to various national initiatives, including the Regulatory Science Netwerk Nederland (Regulatory Science Network Netherlands) and the Regie op Registers voor Dure Geneesmiddelen (control of registrations for expensive drugs). In addition, he is a member/chair of various Data Safety and Monitoring Boards.
Related news items
Young Radboudumc researchers receive grant to engage in bio-medical and health research that is off the beaten path16 September 2021
The ZonMw Off Road program is once again giving young scientists the opportunity to conduct innovative research in medical and/or health care. This research is off the beaten track and aims to bring about new insights and unexpected breakthroughs for healthcare and healthcare innovation.read more
Infections increase risk to develop dementia16 September 2021
In a recently published study, Radboudumc researchers investigated the effects of infectious events on cognitive decline and the development of dementia and its possible structural underpinning using pre- and post-infection MRI of the brain.read more
ENABLECARES launches a course on entrepreneurship for PhD candidates and postdocs15 September 2021
Are you thinking about what to do after your PhD? Want to know more about entrepreneurship? This course gives you insight in many aspects of entrepreneurship and research in industry.read more
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias15 September 2021
Lia Goltstein and colleagues published a study about effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis.read more